WallStreetZenWallStreetZen

NASDAQ: VRDN
Viridian Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VRDN past revenue growth

How has VRDN's revenue growth performed historically?
Company
-82.28%
Industry
151.46%
Market
17.61%
VRDN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VRDN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VRDN's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VRDN earnings and revenue history

Current Revenue
$314.0k
Current Earnings
-$237.7M
Current Profit Margin
-75,711.5%

VRDN Return on Equity

Current Company
-68.3%
Current Industry
-63.5%
Current Market
188%
VRDN's Return on Equity (-68.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VRDN announces earnings.

VRDN Return on Assets

Current Company
-61.1%
Current Industry
2.9%
VRDN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VRDN Return on Capital Employed

Current Company
-50.86%
Current Industry
19.5%
VRDN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VRDN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VRDN$314.00k-$235.32M-$237.73M-48.16%N/A
ABVX$5.02M-$129.52M-$160.59M-38.54%N/A
PHVS$0.00-$103.93M-$108.47MN/AN/A
INVA$310.46M$248.96M$179.72M+3.53%-6.84%
BCRX$331.41M-$116.34M-$226.54M+74.21%N/A
View Top Biotech Stocks

VRDN earnings dates

Next earnings date
May 7, 2024

Viridian Therapeutics Earnings & Revenue FAQ

What were VRDN's earnings last quarter?

On Invalid Date, Viridian Therapeutics (NASDAQ: VRDN) reported Q4 2023 earnings per share (EPS) of -$1.34, up 14.53% year over year. Total Viridian Therapeutics earnings for the quarter were -$66.86 million. In the same quarter last year, Viridian Therapeutics's earnings per share (EPS) was -$1.17.

If you're new to stock investing, here's how to buy Viridian Therapeutics stock.

What was VRDN's earnings growth in the past year?

As of Q2 2024, Viridian Therapeutics's earnings has grown year over year. Viridian Therapeutics's earnings in the past year totalled -$237.73 million.

What is VRDN's earnings date?

Viridian Therapeutics's earnings date is Invalid Date. Add VRDN to your watchlist to be reminded of VRDN's next earnings announcement.

What was VRDN's revenue last quarter?

On Invalid Date, Viridian Therapeutics (NASDAQ: VRDN) reported Q4 2023 revenue of $72.00 thousand up 31.43% year over year. In the same quarter last year, Viridian Therapeutics's revenue was $105.00 thousand.

What was VRDN's revenue growth in the past year?

As of Q2 2024, Viridian Therapeutics's revenue has grown -82.28% year over year. This is 233.74 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Viridian Therapeutics's revenue in the past year totalled $314.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.